Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: June 2010

30 06, 2010

Europe Behind U.S. In Options For Myeloma Therapy

Tags: , , , |2 Comments

Here are the results from a study released this week at a large European Hematology Event in Barcelona, Spain.  I found this on a medical professionals only site, Pharmacy Europe:Phase III studies demonstrate significantly superior progression free survival with continuous revlimid therapy in diagnosed multiple myelomaMonday, June 28, 2010Data presented at the European Haematology Association’s annual congress in

29 06, 2010

More Helpful Info From The IMF: Important News About New High Risk Health Insurance Pools

Tags: , , |2 Comments

Creation of the new national high-risk pool is vitally important to any cancer or multiple myeloma patient who is having trouble finding health insurance.  The International Myeloma Foundation (IMF) has info about the new program available now.  New Information on High Risk Pools from the National Institute of Health Care ReformThe new health reform law

28 06, 2010

IMF Sponsored Multiple Myeloma Video Updates From ASCO.

Tags: , , , , |0 Comments

Here is the link to a Website called Patient Power.  The topic:  Multiple Myeloma Updates From ASCO.This International Myeloma Foundation ACOR video presentation features Dr. Paul Richardson from Dana-Farber Cancer Institute and head of transplantation and Dr. Sergio Giralt from Memorial Sloan-Kettering Cancer Center.  Worth a look!Feel good and keep smiling!  Pat

27 06, 2010

Congress Considering Resolution To Make September "Blood Cancer Awareness Month"

Tags: , |1 Comment

Here is an important announcement from Meghan Buzby, Advocacy Assistant for the International Myeloma Foundation (IMF):Resolution Introduced Recognizing Blood Cancer Awareness Month Representatives Walther Jones (R-NC) and Betsy Markey (D-CO) recently introduced a resolution (H. Res. 1433) designating September 2010 as Blood Cancer Awareness Month. H. Res. 1433 highlights the impact that the blood cancers

26 06, 2010

Insight Into How Cancer Survivors Use Alternative Therapies For Their Health Care Needs

Tags: , |2 Comments

Here is an excerpt from an exceptional article about support for cancer survivors by Helena Oliviero I found on the The Atlanta Journal-Constitution Website:Cancer survivors are living longer and healthier lives. The chance of surviving most cancer has been steadily rising. For example, the 5-year survival rate for breast cancer is now 90 percent, up from

25 06, 2010

Pat Killingsworth To Speak At St. Petersburg Multiple Myeloma Education Group Meeting Saturday, June 26th

Tags: , , |0 Comments

I forgot to mention that I will be speaking to the St. Petersburg Multiple Myeloma Education Group Saturday, June 26th at 10:30 am.The topic:  ASCO updates and practical uses of new novel therapies for multiple myelomaThe group meets at 3221 McMullen Booth Road, Clearwater, Florida, 34695.  Any multiple myeloma patient, caregiver or their family and friends are

25 06, 2010

Revlimid Approved For Use In Relapsed Multiple Myeloma Patients In Japan

Tags: , , , |2 Comments

Celgene's Revlimid is slowly gaining world wide acceptance as a standard of care for relapsed multiple myleloma patients.  It was announced yesterday Japan has officially approved Revlimid's use:REVLIMID® Granted Approval for Treatment of Relapsed or Refractory Multiple Myeloma in Japan Read all about it on Business  My question:  Why is it taking so long

23 06, 2010

Free "Caring For Your Bones When You Have Multiple Myeloma" Workshop Thursday

Tags: , |0 Comments

I wanted to remind my readers about an upcoming CancerCare Connect® Education Workshop, Caring for Your Bones When You Have Multiple Myeloma, which will take place on Thursday, June 24th, from 1:30 to 2:30 pm Eastern Time.Speakers will include William Bensinger, MD, Professor of Medicine, University of Washington, Director, Autologous Stem Cell Transplant Program, Fred

22 06, 2010

Genetic Variations Associated With Treatment Response: A Research Study Presented Last Week At The European Hematology Association Meetings In Spain

Tags: , |0 Comments

More evidence about how a patient's genetic make-up can effect how well they react to treatment:Genetic Variations Influence Patient Response to Treatment for Multiple Myeloma: Presented at EHA  By Jenny Powers for Doctor's GuideBARCELONA, Spain -- June 16, 2010 -- The response to standard therapeutics used for the treatment of patients with multiple myeloma (MM)

21 06, 2010

A Look At Which Multiple Myeloma ASCO News Seemed Most Important To General Cancer Related Sites

Tags: , , , |0 Comments

Medpage Today just ran an article about anti-cancer related advances from ASCO.  I always find it interesting to take a look at what more general cancer related sites consider noteworthy about the world of multiple myeloma.  This extensive article only featured one myeloma related study from ASCO: CHICAGO -- A chemical cousin to the infamous

20 06, 2010

New Research Study Focuses On Antibodies To Stop Multiple Myeloma

Tags: , |0 Comments

Update on another new anti-myeloma research study, post ASCO:Immunomedics doses first patient in Phase I/II multiple myeloma trialImmunomedics, a biopharmaceutical company, has announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma. The open-label, multi-center Phase I/II

18 06, 2010

High Risk Multiple Myeloma Research Studies Featured At ASCO

Tags: , , , |0 Comments

Yesterday I shared part of my conversation/interview with Dr. Ravi Vij, a multiple myeloma specialist with the University of Washington School of Medicine.  The conversation centered on the University of Arkansas Medical Center's intense research into classifying and treating high risk myeloma.Here is a link to the American Society of Clinical Oncology (ASCO) Data Base, connecting

17 06, 2010

University Of Arkansas Medical Center Pushes Advances In High Risk Multiple Myeloma Therapy

Tags: , , , , , , |4 Comments

Before we move on, I wanted to share some of Dr. Ravi Vij's thoughts about UAMS—the University of Arkansas Medical Center. Myeloma docs and researchers there have been developing an aggressive form of anti-myeloma treatment called Total Therapy (TT). Arkansas myeloma specialist, Dr. Barlogie, and other UAMS myeloma researchers are best known for helping newly

16 06, 2010

The Best Time To Get A Stem Cell Transplant For Most Multiple Myeloma Patients: After First Relapse

Tags: , , , , , , |0 Comments

Yesterday I wrote about a conversation I had Monday with Dr. Ravi Vij, Associate Professor, Department of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia Section at the Washington University School of Medicine.  The topic: Our quest to better understand high risk multiple myeloma.Since Dr. Vij works regularly with stem cell transplant (SCT) patients, I

15 06, 2010

Understanding High Risk Multiple Myeloma- Part Two: An Interview With Dr. Ravi Vij

Tags: , , , , , |1 Comment

I spoke by phone Monday evening with Dr. Ravi Vij, Associate Professor, Department of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia Section at the Washington University School of Medicine. The topic: Our quest to better understand high risk multiple myeloma. As you might guess, Dr. Vij has a mild east Asian accent—and we were

13 06, 2010

Thoughts About My Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Dr. Michael Kauffman At ASCO

Tags: , , , , , , , |0 Comments

I started an article about carfilzomib last Tuesday this way:  The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib:"Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask."Well, you just read my interview with Dr. Michael Kauffman,

12 06, 2010

Interview With Onyx Pharmaceuticals’ CMO Dr. Michael Kauffman- Part Two

Tags: , , , , , , |0 Comments

Yesterday I explained why my interview with Dr. Kauffman was so informal. Using a relaxed, conversational style allows me to get a feel for the moment. More than that, I can try to get a sense of how my subject really feels. Are the guarded? Or they hiding something? Are he or she genuinely enthusiastic

11 06, 2010

Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Michael Kauffman- Part One

Tags: , , , , , |4 Comments

As promised, here is Part One of my three part series about last Friday's interview with Dr. Michael Kauffman, Chief Medical Officer/for Onyx Pharmaceuticals, maker of the new proteasome inhibitor, carfilzomib.First, here is what Google has to say about Dr. Kauffman:Director, CombinatoRx, Inc. CMO, Onyx PharmaceuticalsBoston , MA Sector: HEALTHCARE / Biotechnology 46 Years Old